Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mar Environ Res ; 193: 106256, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38006852

ABSTRACT

Widespread habitat-forming invaders inhabiting marinas, such as the spaghetti bryozoan Amathia verticillata, allow exploring facilitation processes across spatiotemporal contexts. Here we investigate the role of this bryozoan as habitat for native and exotic macrofaunal assemblages across different ecoregions of Western Mediterranean and East Atlantic coasts, and a monthly variation over a year. While only 7 (all peracarid crustaceans) of the 54 associated species were NIS, they dominated macrofaunal assemblages in terms of abundance, raising the potential for invasional meltdown. NIS richness and community structure differed among marinas but not among ecoregions, highlighting the importance of marina singularities in modulating facilitation at spatial scale. Despite facilitation did not depend on bryozoan abundance fluctuations, it was affected by its deciduous pattern, peaking in summer and disappearing in late winter. Monitoring A. verticillata in marinas, especially in summer periods, may improve the detection and management of multiple associated NIS.


Subject(s)
Bryozoa , Animals , Introduced Species , Ecosystem , Crustacea , Food
2.
Arch Toxicol ; 92(7): 2275-2295, 2018 07.
Article in English | MEDLINE | ID: mdl-29869127

ABSTRACT

3,4-Methylenedioxymethamphetamine (MDMA or "ecstasy") is a widespread drug of abuse with known neurotoxic properties. The present study aimed to evaluate the differential toxic effects of MDMA in adolescent and aged Wistar rats, using doses pharmacologically comparable to humans. Adolescent (post-natal day 40) (3 × 5 mg/kg, 2 h apart) and aged (mean 20 months old) (2 × 5 mg/kg, 2 h apart) rats received MDMA intraperitoneally. Animals were killed 7 days later, and the frontal cortex, hippocampus, striatum and cerebellum brain areas were dissected, and heart, liver and kidneys were collected. MDMA caused hyperthermia in both treated groups, but aged rats had a more dramatic temperature elevation. MDMA promoted serotonergic neurotoxicity only in the hippocampus of aged, but not in the adolescents' brain, and did not change the levels of dopamine or serotonin metabolite in the striatum of both groups. Differential responses according to age were also seen regarding brain p-Tau levels, a hallmark of a degenerative brain, since only aged animals had significant increases. MDMA evoked brain oxidative stress in the hippocampus and striatum of aged, and in the hippocampus, frontal cortex, and striatum brain areas of adolescents according to protein carbonylation, but only decreased GSH levels in the hippocampus of aged animals. The brain maturational stage seems crucial for MDMA-evoked serotonergic neurotoxicity. Aged animals were more susceptible to MDMA-induced tissue damage in the heart and kidneys, and both ages had an increase in liver fibrotic tissue content. In conclusion, age is a determinant factor for the toxic events promoted by "ecstasy". This work demonstrated special susceptibility of aged hippocampus to MDMA neurotoxicity, as well as impressive damage to the heart and kidney tissue following "ecstasy".


Subject(s)
Aging/drug effects , Brain/drug effects , Fever/chemically induced , N-Methyl-3,4-methylenedioxyamphetamine/toxicity , Neurotoxicity Syndromes/etiology , Aging/metabolism , Animals , Brain/metabolism , Dopamine , Fever/metabolism , Heart/drug effects , Liver/drug effects , Liver/metabolism , Male , Neurotoxicity Syndromes/metabolism , Rats, Wistar , Serotonin
3.
Neurology ; 70(22 Pt 2): 2166-70, 2008 May 27.
Article in English | MEDLINE | ID: mdl-18505995

ABSTRACT

OBJECTIVE: Nonsedating antiepileptic drugs (AEDs) that can be initiated rapidly are desirable in a variety of clinical situations. Levetiracetam (LEV) is a newer AED, with a recently approved parenteral formulation, that can be initiated at doses effective in controlling seizures. We investigated whether oral loading of levetiracetam is well tolerated and facilitates stabilization and discharge of patients in epilepsy monitoring units (EMU). METHODS: Adult patients in the EMU at two centers were identified who received 1,500 mg of LEV in a single dose. This was an observational study of these patients where LEV was thought to be an appropriate component of the therapeutic regimen. Patients were either LEV naive or had been off all LEV for at least 3 days. LEV maintenance was begun 12 hours later at doses of 500 to 1,000 mg twice a day. RESULTS: A total of 37 adult patients (20 female) were identified. There were no spontaneous complaints of side effects. Upon questioning, 33 patients (89%) denied side effects. The remaining 4 patients (11%) reported transient irritability, imbalance, tiredness, or lightheadedness. Eleven patients (mean weight = 85.0 Kg) had mean LEV serum concentration of 31.5 microg/mL after 1 hour, 23 (mean weight 85.7 Kg) had mean concentration of 30.77 microg/mL after 2 hours, five (mean weight 84.3 Kg) had mean concentration of 12.1 microg/mL after 12 hours, and two (mean weight 94 Kg) had mean concentration of 7.4 microg/mL after 14 hours. No seizures occurred within 24 hours of loading. All patients were able to be discharged 3 to 30 hours after loading. CONCLUSIONS: In the population surveyed, oral loading with levetiracetam was well-tolerated and rapidly yielded serum concentrations thought to decrease seizure frequency. This regimen facilitated discharge from the epilepsy monitoring units.


Subject(s)
Anticonvulsants/administration & dosage , Drug Evaluation , Drug Tolerance/physiology , Epilepsy/drug therapy , Piracetam/analogs & derivatives , Administration, Oral , Adolescent , Adult , Aged , Anticonvulsants/blood , Epilepsy/blood , Female , Humans , Levetiracetam , Male , Middle Aged , Piracetam/administration & dosage , Piracetam/blood , Retrospective Studies , Time Factors
4.
Int J Dev Neurosci ; 17(8): 813-20, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10593617

ABSTRACT

Interleukin-1beta (IL-1beta) is a cytokine that regulates a variety of biological processes. In addition to its traditional role in the immune system, IL-1beta plays an integral role in neural-immune and developmental processes in the nervous system. The pleiotropic ability of IL-1beta may be due to the activation of different signal transduction mechanisms in specific cell types or under certain cellular conditions. We have previously demonstrated that IL- regulates healing and repair in the developing, mammalian nervous system. In the damaged perinatal mouse brain, IL-1beta is expressed in astrocytes that change from a stellate to a spindle-shaped morphology. The spindle-shaped astrocytes enclose the wound, separating the healthy from damaged neural tissue. The shape change and subsequent repair processes are IL-1beta activity-dependent, acting through the IL-1 type 1 receptor (IL-1R1), as co-application of the IL-1type 1 receptor antagonist protein (IL-1ra) blocks IL-1beta induced effects. In the C6 astrocytic cell line, IL-1beta induced similar shape changes and upregulated expression of the cytoskeletal protein, glial fibrillary acidic protein (GFAP). Since cytoskeletal changes, as well as specific signal transduction mechanisms, are associated with increases in intracellular calcium ([Ca2+]i), studies were carried out to determine if increases in [Ca2+]i induced by IL-1beta occurred through activation of the IL-1R1 in C6 cells. Cells were treated with IL-1beta and/or IL-1ra, followed by measurement of relative changes in [Ca2+]i using fura-2 fluorescence imaging methods. IL-1beta increased [Ca2+]i levels in a dose and time dependent manner. Treatment with IL-1ra blocked IL-1beta induced increases in [Ca2+]i, indicating that IL-1beta acts through the IL-1R1. Immunocytochemistry experiments showed that untreated C6 cells normally express IL-1beta, IL-1ra, and IL-1RI. Thus, IL-1 system molecules may play a role in normal C6 astrocyte physiology.


Subject(s)
Astrocytes/metabolism , Calcium/metabolism , Interleukin-1/pharmacology , Ion Channel Gating/drug effects , Receptors, Interleukin-1/metabolism , Animals , Antirheumatic Agents/pharmacology , Astrocytes/chemistry , Astrocytes/cytology , Biological Transport/drug effects , Glioma , Immunohistochemistry , Interleukin 1 Receptor Antagonist Protein , Interleukin-1/analysis , Rats , Receptors, Interleukin-1/analysis , Receptors, Interleukin-1/antagonists & inhibitors , Sialoglycoproteins/analysis , Sialoglycoproteins/pharmacology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...